OBJECTIVES: In the European Project on Genes in Hypertension (EPOGH) standardized epidemiological methods were used to determine complex phenotypes consisting of blood pressure (BP) in combination with other traits. In this report, we present the quality control of one of the BP phenotypes. METHODS: In seven European countries eight different research groups recruited random samples of nuclear families. Trained observers measured the BP five times consecutively with the participants in the seated position at each of two separate home visits, 1 to 3 weeks apart, according to the guidelines of the British Hypertension Society. Quality assurance and quality control of this BP phenotype were implemented according to detailed instructions defined in the protocol of the EPOGH study. RESULTS: On 31 August 2001, BP measurements of 2476 subjects were available for analysis. Fewer BP readings than the five planned per visit occurred in one of the eight centres, but only in 0.4% of the home visits. Across centres the relative frequency of identical consecutive readings for systolic or diastolic blood pressure varied from 0 to 6%. The occurrence of odd readings ranged from 0 to 0.1%. Of the 49,488 systolic and diastolic BP readings, 24.0% ended on a zero (expected 20%). In most EPOGH centres there was a progressive decline in the BP from the first to the second home visit. Overall, these decreases averaged 2.36 mmHg [95% confidence interval (CI): 1.98-2.74, P < 0.001] for systolic BP and 1.74 mmHg (95% CI: 1.46-2.02, P < 0.001) for diastolic BP. CONCLUSIONS: Quality assurance and control should be planned at the design stage of a project involving BP measurement and implemented from its very beginnings until the end. The procedures of quality assurance set up in the EPOGH study for the BP measurements resulted in a well-defined BP phenotype, which was consistent across centres. Copyright 2002 Lippincott Williams & Wilkins
OBJECTIVES: In the European Project on Genes in Hypertension (EPOGH) standardized epidemiological methods were used to determine complex phenotypes consisting of blood pressure (BP) in combination with other traits. In this report, we present the quality control of one of the BP phenotypes. METHODS: In seven European countries eight different research groups recruited random samples of nuclear families. Trained observers measured the BP five times consecutively with the participants in the seated position at each of two separate home visits, 1 to 3 weeks apart, according to the guidelines of the British Hypertension Society. Quality assurance and quality control of this BP phenotype were implemented according to detailed instructions defined in the protocol of the EPOGH study. RESULTS: On 31 August 2001, BP measurements of 2476 subjects were available for analysis. Fewer BP readings than the five planned per visit occurred in one of the eight centres, but only in 0.4% of the home visits. Across centres the relative frequency of identical consecutive readings for systolic or diastolic blood pressure varied from 0 to 6%. The occurrence of odd readings ranged from 0 to 0.1%. Of the 49,488 systolic and diastolic BP readings, 24.0% ended on a zero (expected 20%). In most EPOGH centres there was a progressive decline in the BP from the first to the second home visit. Overall, these decreases averaged 2.36 mmHg [95% confidence interval (CI): 1.98-2.74, P < 0.001] for systolic BP and 1.74 mmHg (95% CI: 1.46-2.02, P < 0.001) for diastolic BP. CONCLUSIONS: Quality assurance and control should be planned at the design stage of a project involving BP measurement and implemented from its very beginnings until the end. The procedures of quality assurance set up in the EPOGH study for the BP measurements resulted in a well-defined BP phenotype, which was consistent across centres. Copyright 2002 Lippincott Williams & Wilkins
Authors: Jitka Seidlerová; Murielle Bochud; Jan A Staessen; Marcin Cwynar; Milena Dolejsová; Tatiana Kuznetsova; Tim Nawrot; Agnieszka Olszanecka; Katarzyna Stolarz; Lutgarde Thijs; Wiktoria Wojciechowska; Harry A Struijker-Boudier; Kalina Kawecka-Jaszcz; Robert C Elston; Robert Fagard; Jan Filipovský Journal: J Hypertens Date: 2008-04 Impact factor: 4.844
Authors: Yan Li; Lutgarde Thijs; Zhen-Yu Zhang; Kei Asayama; Tine W Hansen; José Boggia; Kristina Björklund-Bodegård; Wen-Yi Yang; Teemu J Niiranen; Angeliki Ntineri; Fang-Fei Wei; Masahiro Kikuya; Takayoshi Ohkubo; Eamon Dolan; Atsushi Hozawa; Ichiro Tsuji; Katarzyna Stolarz-Skrzypek; Qi-Fang Huang; Jesus D Melgarejo; Valérie Tikhonoff; Sofia Malyutina; Edoardo Casiglia; Yuri Nikitin; Lars Lind; Edgardo Sandoya; Lucas Aparicio; Jessica Barochiner; Natasza Gilis-Malinowska; Krzysztof Narkiewicz; Kalina Kawecka-Jaszcz; Gladys E Maestre; Antti M Jula; Jouni K Johansson; Tatiana Kuznetsova; Jan Filipovský; George Stergiou; Ji-Guang Wang; Yutaka Imai; Eoin O'Brien; Jan A Staessen Journal: Hypertension Date: 2019-10-21 Impact factor: 10.190
Authors: T W Hansen; L Thijs; Y Li; J Boggia; Y Liu; K Asayama; M Kikuya; K Björklund-Bodegård; T Ohkubo; J Jeppesen; C Torp-Pedersen; E Dolan; T Kuznetsova; K Stolarz-Skrzypek; V Tikhonoff; S Malyutina; E Casiglia; Y Nikitin; L Lind; E Sandoya; K Kawecka-Jaszcz; J Filipovský; Y Imai; J Wang; E O'Brien; J A Staessen Journal: J Hum Hypertens Date: 2014-01-16 Impact factor: 3.012
Authors: Ji-Guang Wang; Lifang Liu; Laura Zagato; Jinxiang Xie; Robert Fagard; Kugen Jin; Jinxiang Wang; Yan Li; Giuseppe Bianchi; Jan A Staessen; Lisheng Liu Journal: J Mol Med (Berl) Date: 2004-09-18 Impact factor: 4.599
Authors: Wen-Yi Yang; Jesus D Melgarejo; Lutgarde Thijs; Zhen-Yu Zhang; José Boggia; Fang-Fei Wei; Tine W Hansen; Kei Asayama; Takayoshi Ohkubo; Jørgen Jeppesen; Eamon Dolan; Katarzyna Stolarz-Skrzypek; Sofia Malyutina; Edoardo Casiglia; Lars Lind; Jan Filipovský; Gladys E Maestre; Yan Li; Ji-Guang Wang; Yutaka Imai; Kalina Kawecka-Jaszcz; Edgardo Sandoya; Krzysztof Narkiewicz; Eoin O'Brien; Peter Verhamme; Jan A Staessen Journal: JAMA Date: 2019-08-06 Impact factor: 56.272